Use of isoniazid for latent XXXX in a public health clinic.

@entity1 @entity167 @entity9178 @entity3109 @entity378 @entity99 @entity204
Isoniazid is an efficacious treatment for @entity9178 . Concerns remain, however, regarding hepatotoxicity associated with this medication. In addition, adherence may be suboptimal because at least 6 months of treatment is required. We extracted information from our @entity9178 treatment database to determine adverse effects and treatment completion rates associated with the use of @entity3109 at a county @entity378 clinic. Outcomes were available for 3,788 @entity1 started on isoniazid between 1999 and 2002. Six hundred seventy-two @entity1 (18%) experienced one or more adverse effects, including 10 (0.3%) determined to have isoniazid-associated @entity99 . No hospitalizations or @entity204 occurred in @entity1 experiencing an adverse effect. A higher incidence of adverse effects was associated with increasing age. Sixty-four percent of @entity1 completed at least 6 months of isoniazid. Higher completion rates were associated with younger age, Hispanic ethnicity, and non-U.S. country of birth. Lower completion rates were associated with being homelessness, using excess @entity167 , and having experienced an adverse effect. In summary, we conclude that in our clinic population isoniazid is a safe therapy for @entity9178 , but its effectiveness is limited by modest completion rates.
